Endocyte, Inc. (NASDAQ: ECYT) Investor Lawsuit Filed Over Alleged Wrongdoing In Acquisition

Investors who purchased shares of Endocyte, Inc. (NASDAQ: ECYT) and currently hold any of those NASDAQ: ECYT shares have certain options and should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Case Name: 
Endocyte Deal Case
Case Status: 
Lawsuit Filed
Affected Securities
Lawsuit Overview
Type of Lawsuit: 
Mergers and Acquisition

An investor, who currently holds shares of Endocyte, Inc. (NASDAQ: ECYT), filed a lawsuit against the takeover of Endocyte, Inc.

The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ: ECYT stockholders by agreeing to sell Endocyte, Inc. cheaply via an unfair process.

On October 18, 2018, Endocyte, Inc. (Nasdaq:ECYT) announced that it has entered into an agreement and plan of merger with Novartis AG pursuant to which Novartis will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.
However, plaintiff claims that the proposed consideration NASDAQ: ECYT shareholders will receive is grossly inadequate and undervalues Endocyte, Inc. Indeed, at least one analyst has set the high target price for NASDAQ: ECYT shares at $25.00 per share. In addition, the plaintiff alleges that the process is also unfair Endocyte, Inc. stockholders.